Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1.
Armstrong
P W
PW
University of Alberta, Edmonton, Alberta, Canada. paul.armstrong@ualberta.ca
Collen
D
D
D018849:Controlled Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005337:Fibrin / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008657:Metabolic Clearance Rate; D009203:Myocardial Infarction / Q000188:drug therapy*; D015425:Myocardial Reperfusion / Q000379:methods* / Q000639:trends; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D005337:Fibrin